Rubius Therapeutics Inc

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Cambridge, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rubius Therapeutics is creating RCTs™ as a new class of medicines. Leading applications include programs in cancer, enzyme deficiency diseases and the induction of tolerance to treat autoimmune disease. The company was conceived and launched by Flagship VentureLabs®, the innovation foundry where a team of scientific entrepreneurs systematically evolve enterprising ideas based upon previously undiscovered areas of science into real-world inventions and ventures.

Rubius Therapeutics (NASDAQ: RUBY ) stock is heading higher on Tuesday despite a lack of news from the cellular medicines company. Instead, it looks like increasing interest from traders is behind today's gains as heavy trading takes place.

Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?

Rubius Therapeutics (NASDAQ: RUBY ) stock is falling hard on Tuesday after the biotechnology company received a Nasdaq delisting notice. According to a filing with the U.S. Securities and Exchange Commission (SEC), the company doesn't meet the requirements to list on The Nasdaq Stock Market.

Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?

Dannielle Appelhans to Become President and Chief Executive Officer

Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

Athersys

Faraday Future Intelligent Electric

Which penny stocks are you watching today? The post Hot Penny Stocks to Buy This Week?

Hot Penny Stocks to Buy This Week? 3 to Watch Now

CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT.

Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform

Rubius Therapeutics Announces Strategic Update

Investor Teleconference and Webcast Scheduled Tomorrow, September 13, 2022, at 7:30 a.m. EDT Investor Teleconference and Webcast Scheduled Tomorrow, September 13, 2022, at 7:30 a.m. EDT

Rubius Therapeutics to Provide Strategic Update

IMARA

VistaGen Therapeutics

Here's what you need to know about buying penny stocks on September 9th, 2022 The post 3 High Volume Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 High Volume Penny Stocks To Watch Before Next Week

Rubius Therapeutics, Inc. (RUBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?

New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model

Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open.

Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

BOSTON, July 19, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose "Pepe" Carmona to its Board of Directors. Mr. Carmona brings over 20 years of leadership experience in the biopharmaceutical industry across a range of roles and therapeutic areas.

HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Susanne Schaffert, Ph.D., to its board of directors. Dr. Schaffert brings more than 25 years of experience across clinical development, marketing and sales, finance and commercialization in the global pharmaceutical and biotechnology industries, with a focus on oncology, immuno-oncology and cell therapy. Dr. Schaffert most recently served as President of Novartis Oncology. Also, today, Rubius announced that Anne Prener, M.D., Ph.D., is stepping down from her role on the board of directors, effective today.

Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors

Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression

Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting

Rubius presented unconvincing data at AACR. The stock is down 80% in just 3 months.

Rubius: Poor Data, Punishing Environment, Beaten Stock

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 2:30 p.m. EDT.

Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the Company will present a Trials in Progress poster presentation for its second broad immune stimulation program, RTX-224, at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually from June 3-7, 2022.

Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Noubar Afeyan, Ph.D., co-founder and member of the board of directors of Rubius Therapeutics and chief executive officer of Flagship Pioneering, as chairman of its board of directors. David Epstein who has served as chairman since 2017 will remain a member of the board.

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-(L)1 Refractory Disease

Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results on Tuesday, May 10, 2022, before market open.

Rubius Therapeutics to Announce First Quarter 2022 Financial Results

Aterian

Dogness

Which penny stocks are you watching in May? The post Here Are 3 Penny Stocks You Need to Know About in May 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here Are 3 Penny Stocks You Need to Know About in May 2022

NEW YORK , April 23, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rubius Therapeutics, Inc. - RUBY

Rubius Therapeutics Inc (NASDAQ: RUBY) has announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 trial of RTX-240 in advanced solid tumors. Data were shared at the American Association for Cancer Research Annual Meeting.

Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial

Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or Dose-Limiting Toxicities as of the Cutoff Date

Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the details of its webcast to discuss updated clinical data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors and relapsed/refractory acute myeloid leukemia on April 8, 2022, at 1:15 p.m. ET.

Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET

News for Rubius Therapeutics Inc Stock (RUBY)